<DOC>
	<DOCNO>NCT02603679</DOCNO>
	<brief_summary>The purpose neoadjuvant trial evaluate efficacy toxicity chemotherapy use weekly paclitaxel ( arm A ) versus combination cdk 4/6 inhibitor palbociclib standard endocrine treatment ( arm B ) . After 12 week treatment switch crossover . During 24-weekly treatment period , clinical radiological evaluation perform repeatedly . Switch treatment arm A B allow case lack response due toxicity . A translational subprotocol mandatory part study protocol , except use PET-CT evaluation . Postoperatively , patient receive three 3-weekly course chemotherapy combination epirubicin cyclophosphamide .</brief_summary>
	<brief_title>Neoadjuvant Response-guided Treatment Luminal B-type Tumors Luminal A-type Tumors With Node Metastases</brief_title>
	<detailed_description>Patients randomize either weekly treatment paclitaxel ( arm A ) endocrine treatment combination palbociclib ( arm B ) 12 week . Choice endocrine treatment pre- perimenopausal woman men tamoxifen 20 mg daily , alternatively woman age cohort , LHRH analogue combination aromatase inhibitor , postmenopausal woman treatment aromatase inhibitor . The aromatase inhibitor use accord local practice anastrozole 1 mg daily , exemestane 25 mg daily , letrozole 2.5 mg daily . Pre- perimenopausal woman men treat tamoxifen , alternatively LHRH analogue combination aromatase inhibitor ( woman ) . Postmenopausal woman receive aromatase inhibitor . After 12 week , patient without sign disease progression ( PD ) switch either endocrine treatment combination palbociclib ( arm A ) weekly treatment paclitaxel ( arm B ) 12 week . Postoperatively , patient receive three 3-weekly course chemotherapy combination epirubicin cyclophosphamide . Before start , 6 , 12 , 18 24 week treatment , radiological assessment tumor size perform use mammography ultrasound alt . MRI breast ; PET-CT , confine breast regional lymph node , start , 12 24 week , blood test start , 1 week , 12 , 18 24 week . Physical examination perform start four-weekly week 4 , 8 , 12 , 16 , 20 24 week treatment . In case disease progression ongoing study treatment , individualized management patient 's best interest must consider , case surgery primary option .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>1 . Written inform consent 2 . Female male patient breast cancer confirm histology 3 . Tumor blood sample available . Luminal B type confirm immunohistochemistry , preferably , genomic profiling use NextGeneration Sequencingwith ER ≥120 % Ki67 ≥20 % HER2 amplify , , age 40 young and/or verify lymph node metastasis , luminal A type , define ER PR positive ≥20 % proliferation marker Ki 67 &lt; 20 % HER2 amplify . Any luminal B , Luminal A verified lymph node metastases and/or age 40 young 4 . Age 18 year old . Elderly patient condition adequate plan therapy 5 . Primary breast cancer &gt; 20mm diameter and/or verify regional lymph node metastases 6 . Adequate bone marrow , renal , hepatic cardiac function uncontrolled medical psychiatric disorder 7 . LVEF &gt; 55 % 8 . ECOG performance status 01 9 . Primary breast cancer define p. 5 plus 2 morphologically characterize welldefined distant metastasis accessible stereotactic radiotherapy , provide treatment available 1 . Distant metastasis , include node metastasis contralateral thoracic region mediastinum 2 . Other malignancy diagnose within last five year , except radically treat basal squamous cell carcinoma skin CIS cervix 3 . Patients childbearing age without adequate contraception 4 . Pregnancy lactation 5 . Uncontrolled hypertension , heart , liver , kidney relate medical psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cyclin-Dependent Kinase Inhibitor p16</keyword>
</DOC>